Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Certified by Founder
Lodge
KROMATID®
start up
United States
- Longmont, Colorado
- 21/08/2025
- Series C
- $8,000,000
Revolutionizing gene editing analysis for precision medicine and cutting-edge research.
For cell and gene therapy researchers, biotech and pharma companies, and regulatory professionals, KROMATID’s KROMASURE Platform is the genomic characterization solution that provides high-confidence, single-cell insights into chromosomal integrity, structural variants, and transgene mapping.
Unlike traditional sequencing methods, our technology directly visualizes up to thousands of single cells at a time, offering scalable, actionable data with unprecedented clarity, helping you confidently advance research and meet FDA regulatory requirements.
Visit our website to learn how we can support your research.
- Industry Biotechnology Research
- Website https://kromatid.com/
- LinkedIn https://www.linkedin.com/company/kromatid/
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)